Diagnosis of ovarian carcinoma cell type is highly reproducible: A transcanadian study

American Journal of Surgical Pathology

Volumn 34, Issue 7, 2010, Pages 984-993

  Köbel, Martin ^a   Kalloger, Steve E ^c   Baker, Patricia M ^e   Ewanowich, Carol A ^b   Arseneau, Jocelyne ^f   Zherebitskiy, Viktor ^e   Abdulkarim, Soran ^g   Leung, Samuel ^c   Duggan, Máire A ^a   Fontaine, Dan ^g   Parker, Robin ^d   Huntsman, David G ^c   Gilks, C Blake ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d Lower Mainland Pharmacy Services   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f MCGILL UNIVERSITY   (Canada)

^g MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

cancer; interobserver; ovarian carcinoma; ovary; reproducibility; type

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; CHEMISTRY; CLINICAL TRIAL; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MULTICENTER STUDY; OBSERVER VARIATION; OVARY TUMOR; REPRODUCIBILITY; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; OBSERVER VARIATION; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 77954213625     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181e1a3bb     Document Type: Article

References (34)

1. Al-Hussaini M, Stockman A, Foster H, et al. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Histopathology. 2004;44:109-115.
2. Cramer SF, Roth LM, Ulbright TM, et al. Evaluation of the reproducibility of the World Health Organization classification of common ovarian cancers. With emphasis on methodology. Arch Pathol Lab Med. 1987;111:819-829.
3. Duggan MA, Doig C. Pathology reviews in the research context: future directions. Surgery. 2010. In press.
4. Fountain J, Trimble E, Birrer MJ. Summary and discussion of session recommendations. Gynecol Oncol. 2006;103:S23-S25.
5. Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: recent advances. Hum Pathol. 2009;40:1213-1223.
6. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol. 2008;39:1239-1251.
7. Han G, Gilks CB, Leung S, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohisto-chemical study of 32 cases. Am J Surg Pathol. 2008;32:955-964.
8. Hernandez E, Bhagavan BS, Parmley TH, et al. Interobserver variability in the interpretation of epithelial ovarian cancer. Gynecol Oncol. 1984;17:117-123. (Pubitemid 14176297)
9. Kobel M, Huntsman D, Gilks CB. Critical molecular abnormalities in high-grade serous carcinoma of the ovary. Expert Rev Mol Med. 2008;10:e22.
10. Kobel M, Kalloger SE, Boyd N, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008;5:e232.
11. Kobel M, Kalloger SE, Carrick J, et al. A limited panel of immuno-markers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol. 2009;33:14-21.
12. Kobel M, Kalloger SE, Santos JL, et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol Oncol. 2009;116:50-56.
13. Kobel M, Kalloger SE, Huntsman DG, et al. Differences in tumor cell type in low versus high stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203-211.
14. Kobel M, Langhammer T, Huttelmaier S, et al. Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. Mod Pathol. 2006;19:581-587.
15. Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27:151-160.
16. Lund B, Thomsen HK, Olsen J. Reproducibility of histopathologi-cal evaluation in epithelial ovarian carcinoma. Clinical implications. APMIS. 1991;99:353-358.
17. Madore J, Ren F, Filali-Mouhim A, et al. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma. J Pathol. 2010;220:392-400.
18. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28: 496-504.
19. Malpica A, Deavers MT, Tornos C, et al. Interobserver and intra-observer variability of a two-tier system for grading ovarian serous carcinoma. Am J Surg Pathol. 2007;31:1168-1174.
20. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.
21. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61:152-163.
22. Nagai Y, Inamine M, Hirakawa M, et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol. 2007;107:469-473.
23. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008;8:17.
24. Sakamoto A, Sasaki H, Furusato M, et al. Observer disagreement in histological classification of ovarian tumors in Japan. Gynecol Oncol. 1994;54:54-58.
25. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62:4722-4729.
26. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 2002;21:407-411.
27. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
28. Singer G, Kurman RJ, Chang HW, et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160: 1223-1228.
29. Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003;95:484-486.
30. Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low-and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29:218-224.
31. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol. 2008;27:161-174.
32. Stalsberg H, Abeler V, Blom GP, et al. Observer variation in histo-logic classification of malignant and borderline ovarian tumors. Hum Pathol. 1988;19:1030-1035.
33. Tavassoli FA, Deville P. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the breast and female genital tract. Lyon, PA: IARC Press; 2003:117-145.
34. Vang R, Shih IeM, Salani R, et al. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am J Surg Pathol. 2008; 32:1667-1674.